Product Information
OLMESARTAN MEDOXOMIL 40 MG TAB is a generic product labeled by ScieGen Pharmaceuticals, Inc., priced at $0.1110 per EA under NDC 50228034110. Its NADAC has been published 394 times since Mar 20, 2019.
FDA first approved this application on Jun 29, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40 mg/1
Manufacturer
ScieGen Pharmaceuticals, Inc.NDC
50228034110
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OLMESARTAN MEDOXOMILApproval Type
Generic (ANDA)
FDA Application
ANDA208130FDA Approved
6/29/2018
TE Code
AB
On Market Since
6/29/2018
Pharmacological Classes
Price Statistics
The NADAC for OLMESARTAN MEDOXOMIL 40 MG TAB has been published 394 times since Mar 20, 2019, and over the history we have for it it has declined 36.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1110 per EA |
|---|---|
| All-time high | $0.2064 (Dec 11, 2019) |
| All-time low | $0.1083 (Aug 19, 2026) |
| 52-week high | $0.1235 |
| 52-week low | $0.1083 |
| Median price | $0.1360 |
| Average price | $0.1450 |
| Largest weekly change | -23.1% (Sep 23, 2020) |
| Weeks tracked | 394 |
| Tracking since | Mar 20, 2019 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ScieGen Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
olmesartan medoxomil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OLMESARTAN MEDOXOMIL 40 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for OLMESARTAN MEDOXOMIL 40 MG TAB, manufactured by ScieGen Pharmaceuticals, Inc., is $0.1110 per EA (NDC 50228034110), effective Sep 30, 2026.
How has the price of OLMESARTAN MEDOXOMIL 40 MG TAB changed over time?
Over the history we have for it, the NADAC for OLMESARTAN MEDOXOMIL 40 MG TAB has declined 36.7%. It has been tracked across 394 weekly CMS publications since Mar 20, 2019.
What are the highest and lowest recorded NADAC prices for OLMESARTAN MEDOXOMIL 40 MG TAB?
Since Mar 20, 2019, the NADAC for OLMESARTAN MEDOXOMIL 40 MG TAB has ranged from a low of $0.1083 (Aug 19, 2026) to a high of $0.2064 (Dec 11, 2019), with a median of $0.1360 per EA.
Are there cheaper alternatives to OLMESARTAN MEDOXOMIL 40 MG TAB?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, OLMESARTAN MEDOXOMIL 40 MG TAB, is $0.1101 per EA — about 1% below OLMESARTAN MEDOXOMIL 40 MG TAB.
Who manufactures OLMESARTAN MEDOXOMIL 40 MG TAB?
OLMESARTAN MEDOXOMIL 40 MG TAB (NDC 50228034110) is labeled by ScieGen Pharmaceuticals, Inc., and CMS classifies it as a generic product.